NI201700068A - Composiciones anticancerosas - Google Patents
Composiciones anticancerosasInfo
- Publication number
- NI201700068A NI201700068A NI201700068A NI201700068A NI201700068A NI 201700068 A NI201700068 A NI 201700068A NI 201700068 A NI201700068 A NI 201700068A NI 201700068 A NI201700068 A NI 201700068A NI 201700068 A NI201700068 A NI 201700068A
- Authority
- NI
- Nicaragua
- Prior art keywords
- rna
- prostate cancer
- hpmcas
- meth
- poly
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a formulaciones farmacéuticas de ARN-509, que pueden administrarse a un mamífero, particularmente a un ser humano, que sufre una enfermedad o afección relacionada con un receptor de andrógenos (RA), particularmente cáncer, más particularmente cáncer de próstata, que incluye pero sin limitarse a, cáncer de próstata resistente a la castración, cáncer de próstata metastásico resistente a la castración, cáncer de próstata metastásico resistente a la castración sin previo tratamiento quimioterapéutico, cáncer de próstata sensible a hormonas bioquímicamente reincidido, o de alto riesgo, cáncer de próstata no metastásico resistente a la castración. En un aspecto, estas formulaciones comprenden una dispersión sólida de ARN-509, un copolímero de poli(met)acrilato y HPMCAS. En un aspecto, la dispersión sólida de ARN-509, un copolímero de poli(met)acrilato y HPMCAS pueden obtenerse y particularmente se obtienen por extrusión por fusión de una mezcla que comprende ARN-509, un copolímero de poli(met)acrilato y HPMCAS, y opcionalmente posterior molido de dicha mezcla extruida por fusión. En un aspecto, la dispersión sólida de ARN-509, un copolímero de poli(met)acrilato y HPMCAS puede obtenerse y particularmente se obtiene, mediante el secado por aspersión de una mezcla que comprende ARN-509, un copolímero de poli(met)acrilato y HPMCAS en un solvente adecuado.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14196605 | 2014-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201700068A true NI201700068A (es) | 2017-09-11 |
Family
ID=52006907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201700068A NI201700068A (es) | 2014-12-05 | 2017-06-02 | Composiciones anticancerosas |
Country Status (33)
Country | Link |
---|---|
US (3) | US10285948B2 (es) |
EP (2) | EP3925598A1 (es) |
JP (1) | JP6830892B2 (es) |
KR (1) | KR102387089B1 (es) |
CN (1) | CN106999432A (es) |
AR (1) | AR102925A1 (es) |
AU (1) | AU2015358497B2 (es) |
CA (1) | CA2969675C (es) |
CL (1) | CL2017001373A1 (es) |
CO (1) | CO2017005574A2 (es) |
CR (1) | CR20170218A (es) |
CY (1) | CY1124504T1 (es) |
DK (1) | DK3226843T3 (es) |
EA (1) | EA201791251A1 (es) |
ES (1) | ES2883187T3 (es) |
HR (1) | HRP20211140T1 (es) |
HU (1) | HUE054935T2 (es) |
IL (1) | IL252325A0 (es) |
LT (1) | LT3226843T (es) |
MA (1) | MA41111B1 (es) |
MD (1) | MD3226843T2 (es) |
MX (1) | MX2017007206A (es) |
MY (1) | MY192931A (es) |
NI (1) | NI201700068A (es) |
PH (1) | PH12017500979A1 (es) |
PL (1) | PL3226843T3 (es) |
PT (1) | PT3226843T (es) |
RS (1) | RS62421B1 (es) |
SG (1) | SG11201704386VA (es) |
SI (1) | SI3226843T1 (es) |
TW (1) | TWI709403B (es) |
UA (1) | UA123538C2 (es) |
WO (1) | WO2016090105A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2885415C (en) | 2012-09-26 | 2021-06-29 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
EP3925598A1 (en) | 2014-12-05 | 2021-12-22 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
CA3079135A1 (en) | 2017-10-16 | 2019-04-25 | Arturo Molina | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
WO2020144646A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Apalutamide dispersed in applesauce for treating prostate cancer |
SG11202107712SA (en) | 2019-01-30 | 2021-08-30 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
BR112021014657A2 (pt) | 2019-01-30 | 2021-09-21 | Janssen Pharmaceutica N.V. | Métodos para tratar câncer de próstata com base em subtipos moleculares |
WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
EP4054572A1 (en) | 2019-11-04 | 2022-09-14 | Aragon Pharmaceuticals, Inc. | Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment |
WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
WO2022049523A1 (en) | 2020-09-04 | 2022-03-10 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ249911A (en) | 1992-03-31 | 1996-06-25 | British Tech Group | 17-(3-pyridyl) substituted steroids and use in pharmaceutical compositions |
DE69837903T2 (de) | 1997-08-11 | 2008-02-14 | Pfizer Products Inc., Groton | Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit |
WO2001060410A1 (fr) | 2000-02-21 | 2001-08-23 | Takeda Chemical Industries, Ltd. | Preparations a liberation lente contenant un compose physiologiquement actif peu soluble dans l'eau et methode de production et d'utilisation desdites preparations |
CN1503662A (zh) | 2001-02-27 | 2004-06-09 | 药物制剂 | |
HUP0303454A3 (en) | 2001-04-02 | 2005-12-28 | Astrazeneca Ab | Solid pharmaceutical composition comprising 4-cyano-trifluoro-3(4-fluorophenyl-sulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp |
EA200301250A1 (ru) | 2001-06-22 | 2004-06-24 | Пфайзер Продактс Инк. | Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры |
SE0103424D0 (sv) | 2001-10-15 | 2001-10-15 | Astrazeneca Ab | Pharmaceutical formulation |
RU2288703C2 (ru) | 2002-02-01 | 2006-12-10 | Пфайзер Продактс Инк. | Способ создания однородных высушенных распылением твердых аморфных лекарственных дисперсных систем с использованием распыляющих напорных форсунок (варианты) и продукт |
WO2003077827A1 (fr) | 2002-03-19 | 2003-09-25 | Nippon Shinyaku Co., Ltd. | Procede de production de medicament solide en dispersion |
CN1878539B (zh) | 2003-12-15 | 2010-06-23 | 科学与工业研究委员会 | 含苦味药物和pH敏感性聚合物的掩味的药物组合物 |
PT2656842T (pt) | 2006-03-27 | 2016-10-04 | Univ California | Modulador do recetor de androgénios para o tratamento de cancro da próstata e doenças associadas ao recetor de androgénios |
JP5511942B2 (ja) * | 2009-04-03 | 2014-06-04 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | 組成物及びその使用 |
EP2824102B1 (en) | 2010-02-16 | 2017-02-01 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
CN102525876B (zh) * | 2010-12-15 | 2014-03-12 | 西安力邦医药科技有限责任公司 | 阿司匹林固体分散体、其制备方法、药物组合物和用途 |
EP3333153A1 (en) | 2011-06-15 | 2018-06-13 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
US20150037407A1 (en) | 2012-03-21 | 2015-02-05 | Emphascience, Inc. | Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy |
WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
NZ717683A (en) * | 2012-06-07 | 2018-04-27 | Aragon Pharmaceuticals Inc | Crystalline forms of an androgen receptor modulator |
US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
CN104981483B (zh) | 2012-08-24 | 2017-10-24 | 陶氏环球技术有限责任公司 | 新的羟烷基甲基醋酸琥珀酸纤维素 |
EA033374B9 (ru) | 2012-09-11 | 2019-12-18 | Медивейшн Простейт Терапьютикс Ллк | Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения |
US9977033B2 (en) | 2012-09-11 | 2018-05-22 | The Board Of Regents Of The University Of Texas System | Methods for assessing cancer recurrence |
CA2885415C (en) * | 2012-09-26 | 2021-06-29 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
MX2015008911A (es) | 2013-01-22 | 2015-10-22 | Hoffmann La Roche | Composicion farmaceutica con biodisponibilidad mejorada. |
SG11201507681PA (en) | 2013-03-15 | 2015-10-29 | Iceutica Inc | Abiraterone acetate formulation |
WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
BR112016002970A2 (pt) | 2013-08-12 | 2017-09-12 | Tokai Pharmaceuticals Inc | biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio |
WO2015116696A1 (en) * | 2014-01-28 | 2015-08-06 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
CN106102716A (zh) * | 2014-02-05 | 2016-11-09 | 斯洛文尼亚莱柯制药股份有限公司 | 雄激素受体拮抗剂的固体药物组合物 |
BR112016018288A2 (pt) | 2014-02-06 | 2017-10-10 | Hoffmann La Roche | proteínas de fusão de interleucina 2 e uso das mesmas |
TWI831347B (zh) | 2014-08-08 | 2024-02-01 | 日商中外製藥股份有限公司 | 包含4環性化合物的非晶質體之固體分散體及製劑 |
MA41108B1 (fr) | 2014-12-05 | 2021-03-31 | Aragon Pharmaceuticals Inc | Compositions anticancéreuses |
EP3925598A1 (en) | 2014-12-05 | 2021-12-22 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
MA41107A (fr) | 2014-12-05 | 2017-10-10 | Aragon Pharmaceuticals Inc | Compositions anti-cancéreuses |
CN109219437A (zh) * | 2016-06-03 | 2019-01-15 | 阿拉贡药品公司 | 抗癌组合物 |
-
2015
- 2015-12-03 EP EP21175525.1A patent/EP3925598A1/en active Pending
- 2015-12-03 CN CN201580066235.3A patent/CN106999432A/zh active Pending
- 2015-12-03 SG SG11201704386VA patent/SG11201704386VA/en unknown
- 2015-12-03 TW TW104140459A patent/TWI709403B/zh not_active IP Right Cessation
- 2015-12-03 MX MX2017007206A patent/MX2017007206A/es unknown
- 2015-12-03 MY MYPI2017701986A patent/MY192931A/en unknown
- 2015-12-03 CA CA2969675A patent/CA2969675C/en active Active
- 2015-12-03 WO PCT/US2015/063671 patent/WO2016090105A1/en active Application Filing
- 2015-12-03 HU HUE15820351A patent/HUE054935T2/hu unknown
- 2015-12-03 UA UAA201707015A patent/UA123538C2/uk unknown
- 2015-12-03 MD MDE20170154T patent/MD3226843T2/ro unknown
- 2015-12-03 CR CR20170218A patent/CR20170218A/es unknown
- 2015-12-03 AU AU2015358497A patent/AU2015358497B2/en active Active
- 2015-12-03 JP JP2017529774A patent/JP6830892B2/ja active Active
- 2015-12-03 LT LTEP15820351.3T patent/LT3226843T/lt unknown
- 2015-12-03 PL PL15820351T patent/PL3226843T3/pl unknown
- 2015-12-03 SI SI201531686T patent/SI3226843T1/sl unknown
- 2015-12-03 ES ES15820351T patent/ES2883187T3/es active Active
- 2015-12-03 EP EP15820351.3A patent/EP3226843B1/en active Active
- 2015-12-03 RS RS20211035A patent/RS62421B1/sr unknown
- 2015-12-03 EA EA201791251A patent/EA201791251A1/ru unknown
- 2015-12-03 KR KR1020177018243A patent/KR102387089B1/ko active IP Right Grant
- 2015-12-03 DK DK15820351.3T patent/DK3226843T3/da active
- 2015-12-03 MA MA41111A patent/MA41111B1/fr unknown
- 2015-12-03 US US15/533,229 patent/US10285948B2/en active Active
- 2015-12-03 PT PT158203513T patent/PT3226843T/pt unknown
- 2015-12-04 AR ARP150103981A patent/AR102925A1/es unknown
-
2017
- 2017-05-16 IL IL252325A patent/IL252325A0/en unknown
- 2017-05-26 PH PH12017500979A patent/PH12017500979A1/en unknown
- 2017-05-29 CL CL2017001373A patent/CL2017001373A1/es unknown
- 2017-06-02 NI NI201700068A patent/NI201700068A/es unknown
- 2017-06-05 CO CONC2017/0005574A patent/CO2017005574A2/es unknown
-
2019
- 2019-03-19 US US16/357,821 patent/US11224575B2/en active Active
-
2021
- 2021-03-15 US US17/201,811 patent/US11911511B2/en active Active
- 2021-07-19 HR HRP20211140TT patent/HRP20211140T1/hr unknown
- 2021-08-13 CY CY20211100730T patent/CY1124504T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201700068A (es) | Composiciones anticancerosas | |
NI201700069A (es) | Composiciones anticancerosas | |
CO2017005572A2 (es) | Composiciones anticancerígenas | |
NI201800127A (es) | Composiciones antineoplásicas | |
CU20170045A7 (es) | Anticuerpos agonistas de anti-gitr y composiciones de los mismos | |
CL2011002942A1 (es) | Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer. | |
EA201792304A1 (ru) | Комбинированная терапия для лечения рака | |
CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
CY1117660T1 (el) | Εξουδετερωτικο αντισωμα υποδοχεα προλακτινης ματ3 και η θεραπευτικη χρηση αυτου | |
UY32822A (es) | Composiciones farmacéuticas para el tratamiento de cáncer y otras enfermedades o trastornos | |
MX2020003126A (es) | Derivados de iminopirimidina ciclicos como inhibidores de cinasa. | |
EA201691053A1 (ru) | Соединения к рецептору фактора роста фибробластов 3 типа (fgfr3) и способы терапии | |
CL2011000168A1 (es) | Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer. | |
CO2018011420A2 (es) | Formulaciones líquidas de fosfaplatino | |
AR108690A1 (es) | Anticuerpos contra el miembro 21 de la superfamilia del receptor del factor de necrosis tumoral (anti-tnfrsf21) y métodos de uso de los mismos |